Melanotan 1: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 11 sources cited

Overview

Melanotan-1 (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanogenesis, producing a protective tan without UV exposure. It is FDA-approved under the brand name Scenesse for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike Melanotan-2, it is highly selective for the MC1 receptor and does not produce significant sexual or appetite-related side effects.

Mechanism of Action

Melanotan-1 is a linear 13-amino-acid peptide analog of α-MSH with a substitution at position 4 (Nle) and position 7 (D-Phe) that dramatically increases its potency and metabolic stability compared to native α-MSH. It selectively binds to and activates the melanocortin-1 receptor (MC1R), which is predominantly expressed on melanocytes in the basal layer of the epidermis. Upon MC1R activation, intracellular cAMP levels rise via adenylyl cyclase, activating protein kinase A (PKA) and subsequently the transcription factor CREB. This cascade upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis, which drives expression of tyrosinase and related enzymes responsible for converting tyrosine to eumelanin — the dark, photoprotective pigment. Unlike pheomelanin (red/yellow pigment), eumelanin absorbs UV radiation efficiently and scavenges reactive oxygen species, providing genuine photoprotection. Melanotan-1's selectivity for MC1R over MC3R, MC4R, and MC5R means it produces melanogenesis with minimal effects on appetite, sexual function, or cardiovascular parameters. The peptide also demonstrates anti-inflammatory properties through melanocortin signaling, reducing IL-6 and TNF-α in UV-exposed skin.

Melanotan 1 Benefits: What the Research Shows

  • A pivotal Phase III trial published in the New England Journal of Medicine (2015) demonstrated afamelanotide significantly increased pain-free time in sunlight for EPP patients compared to placebo
  • Barnetson et al. (2006) in the Journal of Investigative Dermatology showed Melanotan-1 increased melanin density by an average of 41% in the fairest-skinned subjects and reduced sunburn cells and UV-induced DNA damage after three 10-day injection cycles over 3 months
  • Research in Photochemistry and Photobiology (2000) measured a significant rise in skin eumelanin, but not pheomelanin, after 10 daily injections in seven volunteers; the FDA label states this occurs independently of UV exposure, distinguishing it from conventional tanning
  • Cell studies have shown that α-MSH and related MC1R agonists reduce UV-induced DNA damage and cell death in cultured human melanocytes (Journal of Biological Chemistry, 2005; FASEB Journal, 2006)
  • A 2015 British Journal of Dermatology observational study of 115 EPP patients receiving implants for up to 8 years found sustained improvement in quality of life and only minor side effects
  • Preclinical research indicates MC1R activation may reduce risk of melanoma by promoting DNA repair in melanocytes exposed to UV radiation

Melanotan 1 Dosage

  • FDA-approved (Scenesse): 16 mg subcutaneous implant every 60 days for EPP patients
  • Research/off-label protocol: 0.5–1.0 mg subcutaneous injection daily for 10–14 days as a loading phase
  • Maintenance dose: 0.5–1.0 mg every 2–3 days after desired pigmentation is achieved
  • Some protocols use 1 mg daily for 7 days, then taper to twice weekly
  • Best administered 30–60 minutes before bed to minimize nausea
  • Moderate UV exposure (10–20 min) during the loading phase accelerates pigmentation results
  • Typical cycle: 4–8 weeks loading, then as-needed maintenance
  • Start with a lower dose (0.25–0.5 mg) to assess tolerance before escalating
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Melanotan 1 Side Effects & Safety

Known Side Effects

  • Nausea — most common side effect, typically mild and dose-dependent, usually subsides after the first few doses
  • Facial flushing — transient redness lasting 30–60 minutes post-injection, mediated by peripheral vasodilation
  • Darkening of existing moles and freckles — requires monitoring for atypical changes
  • Injection site reactions — minor redness, swelling, or soreness at the subcutaneous injection site
  • Fatigue and drowsiness — reported by some users, particularly when dosing in the evening
  • Headache — occasional, usually during the loading phase and resolves with continued use

Safety Profile

Melanotan-1 has a strong safety profile supported by regulatory approval (FDA, EMA) for EPP. Controlled trials in 244 adults with EPP and an observational study of 115 patients treated for up to 8 years found mostly mild side effects, though serious allergic reactions, including anaphylaxis, have been reported since approval. The most common side effects are nausea and injection site reactions, both generally mild and self-limiting. Because it stimulates melanogenesis, existing nevi (moles) may darken, and dermatological monitoring is recommended during use — a full-body skin exam before starting and every 6 months during prolonged use is prudent. Unlike Melanotan-2, it does not significantly affect blood pressure, sexual arousal, or appetite due to its MC1R selectivity. The FDA label's only contraindication is a previous severe allergic reaction to the drug, and the EMA states it must not be used in people with reduced liver or kidney function. Benefit was maintained over years of repeated implants in the long-term observational study. No drug interaction studies have been conducted, and concurrent use of photosensitizing medications should be approached with caution.

What to Expect

Week 1: Mild nausea may occur with initial injections, usually subsiding by day 3–4. No visible pigmentation changes yet, though melanocyte activation has begun at the cellular level. Week 2: Faint darkening of existing freckles and moles becomes noticeable. Skin may appear to have a very subtle warm undertone. Nausea should have resolved. Weeks 3–4: Visible tan developing, especially in areas with prior UV exposure. The tan deepens progressively and has a natural-appearing eumelanin tone (brown, not orange). Weeks 5–8: Full pigmentation achieved for most users. The tan is even and provides measurable UV protection. Maintenance dosing begins, and pigmentation can be sustained with infrequent injections. After cessation, the tan fades gradually over 1–2 months as melanized keratinocytes naturally shed through epidermal turnover.

Common Stacks

Storage & Handling

Store lyophilized powder at -20°C for long-term storage (up to 24 months) or 2–8°C (refrigerated) for up to 6 months. Reconstitute with bacteriostatic water (0.9% benzyl alcohol). After reconstitution, store refrigerated at 2–8°C and use within 4–6 weeks. Do not freeze reconstituted solution. Protect from light — melanocortin peptides are photosensitive. Use sterile technique during reconstitution to prevent contamination.

Pricing & Available Variants

$40price range
10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Scenesse (afamelanotide) implant, for subcutaneous use: prescribing information. Clinuvel, via DailyMed. 2026.
  2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015.
  3. Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015.
  4. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006.
  5. Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000.
  6. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991.
  7. Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997.
  8. Böhm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005.
  9. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006.
  10. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, et al. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res. 2005.
  11. Scenesse (afamelanotide): EPAR medicine overview. European Medicines Agency. 2014.

Related Peptides

Track Melanotan 1 in Your Protocol

Log your Melanotan 1 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free